Literature DB >> 20711219

Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.

Juan Jin1, Yan Chang, Wei Wei.   

Abstract

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease that dramatically impairs quality of life. A number of compounds are available to treat RA, but they vary in effectiveness. Thus, no optimal treatment strategy has been defined. Currently, disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents are considered the treatments of choice. For patients with inadequate responses to DMARD therapy, one recommended therapeutic alternative is anti-TNF-alpha therapy. Anti-TNF-alpha agents are effective and have rapid onset of action compared with DMARDs. Elucidating the differences in effectiveness of anti-TNF-alpha compounds has important clinical implications. By comparing the efficacy, safety and use principle of different treatment options, this review focuses on providing important information about three anti-TNF-alpha compounds (etanercept, infliximab, and adalimumab) to help define optimal treatments for RA patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20711219      PMCID： PMC4002310          DOI： 10.1038/aps.2010.134

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   6.150


  70 in total

1.  The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.

Authors:  Estella Musacchio; Chiara Valvason; Constantin Botsios; Francesca Ostuni; Antonio Furlan; Roberta Ramonda; Valentina Modesti; Leonardo Sartori; Leonardo Punzi
Journal:  J Rheumatol       Date:  2009-06-30       Impact factor: 4.666

2.  Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  K L Hyrich; K D Watson; A J Silman; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2006-05-16       Impact factor: 7.580

3.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

4.  Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.

Authors:  Boulos Haraoui; Edward C Keystone; J Carter Thorne; Janet E Pope; Isaac Chen; Charles G Asare; Jonathan A Leff
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

5.  Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

Authors:  M L Hetland; H M Lindegaard; A Hansen; J Pødenphant; J Unkerskov; V S Ringsdal; M Østergaard; U Tarp
Journal:  Ann Rheum Dis       Date:  2008-02-13       Impact factor: 19.103

6.  The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.

Authors:  D van der Heijde; G Burmester; J Melo-Gomes; C Codreanu; E Martin Mola; R Pedersen; B Freundlich; D J Chang
Journal:  Ann Rheum Dis       Date:  2007-08-29       Impact factor: 19.103

7.  Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.

Authors:  Anne Grimstvedt Kvalvik; Liv Lefsaker; Siri Dyvik; Johan Gorgas Brun
Journal:  Joint Bone Spine       Date:  2007-08-09       Impact factor: 4.929

8.  Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment.

Authors:  Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen
Journal:  Rheumatol Int       Date:  2007-09-06       Impact factor: 2.631

9.  An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.

Authors:  Antonio Julià; Alba Erra; Carles Palacio; Carlos Tomas; Xavier Sans; Pere Barceló; Sara Marsal
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

10.  A systematic review of infliximab in the treatment of early rheumatoid arthritis.

Authors:  Sophie Martin Du Pan; Cem Gabay; Axel Finckh
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
View more
  16 in total

1.  Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoid.

Authors:  Eric Assier; Luca Semerano; Emilie Duvallet; Laure Delavallée; Emilie Bernier; Marion Laborie; Géraldine Grouard-Vogel; Patrick Larcier; Natacha Bessis; Marie-Christophe Boissier
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Simian immunodeficiency virus-induced alterations in monocyte production of tumor necrosis factor alpha contribute to reduced immune activation in sooty mangabeys.

Authors:  Kiran D Mir; Steven E Bosinger; Melanie Gasper; On Ho; James G Else; Jason M Brenchley; David J Kelvin; Guido Silvestri; Shiu-Lok Hu; Donald L Sodora
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

Review 3.  Mediators of oligodendrocyte differentiation during remyelination.

Authors:  Jigisha R Patel; Robyn S Klein
Journal:  FEBS Lett       Date:  2011-04-29       Impact factor: 4.124

Review 4.  Autophagy and apoptosis cascade: which is more prominent in neuronal death?

Authors:  Rohan Gupta; Rashmi K Ambasta
Journal:  Cell Mol Life Sci       Date:  2021-11-06       Impact factor: 9.261

5.  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

Authors:  Jack T Stapleton; Nancy Wagner; Rebecca Tuetken; Abbie R Bellamy; Heather Hill; Sonnie Kim; Patricia L Winokur
Journal:  Vaccine       Date:  2020-04-12       Impact factor: 3.641

Review 6.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

7.  Associations of Circulating Soluble Tumor Necrosis Factor-α Receptors 1 and 2 with Interleukin-6 Levels in an Aging Cohort of Injection Drug Users with or at High Risk for HIV Infection.

Authors:  Sean X Leng; Stewart Dandorf; Huifen Li; Joshua Carlson; Jessica Hui; Shruti H Mehta; Damani Piggott; Salequl Islam; Bhavish Manwani; Gregory D Kirk
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-13       Impact factor: 2.205

8.  Differential control of Helios(+/-) Treg development by monocyte subsets through disparate inflammatory cytokines.

Authors:  Hui Zhong; Karina Yazdanbakhsh
Journal:  Blood       Date:  2013-01-30       Impact factor: 22.113

9.  Phellinus baumii ethyl acetate extract alleviated collagen type II induced arthritis in DBA/1 mice.

Authors:  Taddesse Yayeh; Whi Min Lee; Dukhwan Ko; Seung-Choon Park; Jae Youl Cho; Hwa-Jin Park; In-Kyoung Lee; Seung-Hyung Kim; Seung-Bok Hong; Suk Kim; Bong-Sik Yun; Man Hee Rhee
Journal:  J Nat Med       Date:  2013-03-06       Impact factor: 2.343

10.  Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking.

Authors:  Liang Liang Bai; Hao Chen; Peng Zhou; Jun Yu
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.